Hua Medicine Ltd. (2552)

Overview

Hua Medicine (Shanghai) Ltd. is a pioneering drug development company, ingrained in the heart of China's booming pharmaceutical industry. Established in 2011 and headquartered in Beijing, Hua Medicine dedicates its efforts to crafting innovative therapeutic solutions, predominantly targeting diabetes, a burgeoning health crisis in China as well as globally. The company distinguishes itself through its focus on developing novel oral drug formulations and combinations that address the multifaceted challenges of diabetes management. Leveraging cutting-edge scientific research and clinical trials, Hua Medicine aims to enhance the quality of life for millions living with this chronic condition, weaving a new narrative in diabetes care that is both effective and accessible.

Products and Services

At the core of Hua Medicine's product pipeline are several breakthrough treatments, each specifically designed to offer a unique approach to managing and potentially reversing diabetes and its associated complications. Key offerings include:

• Dorzagliatin (HMS5552): This oral medication represents a cornerstone in Hua Medicine’s approach to Type 2 Diabetes (T2D) treatment. It is designed to restore the glucose sensitivity of pancreatic beta-cells, thus improving glycemic control in patients.
• Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin: These combination therapies amplify the efficacy of Dorzagliatin by pairing it with other established diabetes treatments, targeting various mechanisms of the disease to achieve better glycemic control in T2D patients.
• Dorzagliatin in combination with Pioglitazone for NASH (Non-alcoholic Steatohepatitis): This innovative combo therapy extends the therapeutic reach of Dorzagliatin beyond diabetes, aiming at treating NASH, a common co-morbidity associated with insulin resistance.
• Dorzagliatin in combination with GLP-1 for Alzheimer's diseases: Leveraging the link between diabetes and neurodegenerative diseases, this combination explores the potential of Dorzagliatin to mitigate symptoms or slow the progression of Alzheimer's disease.
• Dorzagliatin in combination with Insulin for late-stage T2D and Type 1 Diabetes (T1D): Targeting more advanced stages of diabetes, this combination seeks to improve glucose management for individuals requiring insulin therapy.
• mGLUR5 for the treatment of Parkinson’s disease: Moving beyond diabetes care, Hua Medicine is also developing treatments for Parkinson’s disease, focusing on the metabotropic glutamate receptor 5 (mGLUR5) as a novel target.
• Fructokinase Inhibitor for Metabolic disease: Addressing a broader range of metabolic disorders, this therapy targets fructokinase, an enzyme involved in fructose metabolism, suggesting a potential pathway to treat or prevent metabolic diseases.